Keen Vision Acquisition Corporation Units

The M&A Class Action Firm is investigating the proposed mergers of NorthStar Healthcare Income, Keen Vision Acquisition Corp., Altus Power, and Aerovate Therapeutics, providing information and options for shareholders.

Medera, a clinical-stage biopharmaceutical company, has completed patient dosing in its Phase 1/2a MUSIC-HFrEF trial of the gene therapy candidate SRD-001 for heart failure with reduced ejection fraction. The preliminary data showed an acceptable safety profile and clinically meaningful improvements in heart function and patient health.

Medera, Inc., a clinical-stage biotechnology company, announced that its management team will participate in two upcoming investor conferences in February 2025. The company is focused on developing next-generation gene and cell-based therapies for difficult-to-treat diseases.